| Study | Reason for exclusion |
|---|---|
| Barkai 1985 | Allocation: not randomised (not an intervention study, review article). |
| Beasley 1998 | Allocation: randomised. Participants: people with psychosis. Intervention: olanzapine vs haloperidol vs placebo, not antiglucocorticoid or related intervention. |
| Belanoff 2002 | Allocation: randomised. Participants: people with psychotic major depression. Intervention: dose finding study (50 mg to 400 mg of mifepristone), not a placebo‐controlled trial. |
| Brambilla 1988 | Allocation: not randomised (all participantts were allocated to receive placebo treatment first, followed by the intervention treatment). |
| David 1999 | Allocation: randomised. Participants: people with psychosis. Intervention: olanzapine vs risperidone, not antiglucocorticoid or related intervention. |
| Harrigan 2004 | Allocation: randomised.
Participants: people with a psychotic disorder. Interventions: not an intervention study (ketoconazole administered as CYP inhibitor to examine antipsychotic effects on cardiac functioning measures). |
| Iager 1986 | Allocation: randomised. Participants: people with psychosis. Intervention: 1‐desamino‐8‐D‐arginine vasopressin (DDAVP) vs placebo, not antiglucocorticoid or related intervention. |
| Katz 2002 | Allocation: not randomised (not an intervention study, review article). |
| Kim 1960 | Allocation: not randomised (case control study). |
| Kline 1968 | Allocation: not randomised. |
| Korsgaard 1981 | Allocation: not randomised (all participantts were allocated to receive placebo treatment first, followed by the intervention treatment). |
| Lane 2001 | Allocation: randomised. Participants: people with schizophrenia. Intervention: clozapine plus water vs clozapine plus super‐strength grapefruit juice, not antiglucocorticoid or related intervention. |
| Lembke 2013 | Allocation: not randomised (not an intervention study). |
| Loranger 1968 | Allocation: randomised. Participants: mixed diagnostic group (diagnoses: schizophrenic reaction (50%), psychoneurotic reaction (22%), manic‐depressive reaction (18%), sociopathic personality disturbance (5%), involutional psychotic reaction (3%), 'paranoid state' (2%). Interventions: cyclopregnol (6beta‐hydroxy‐3,5‐cyclopregnan‐20‐one) vs chlorpromazine vs placebo, not antiglucocorticoid or related intervention. |
| Miodownik 2011 | Allocation: randomised. Participants: schizophrenia, schizoaffective disorder. Intervention: L‐theanine vs placebo. Reason for exclusion: not an antiglucocorticoid treatment. |
| Nihalani 2007 | Allocation: not randomised (not an intervention study, review article). |
| Rees 1951 | Allocation: not randomised (case control study). |
| Rees 1956 | Allocation: not randomised (case control study). |
| Rothschild 2005 | Allocation: not randomised (not an intervention study, letter to the editor). |
| Schatzberg 2003 | Allocation: not randomised (not an intervention study, review article). |
| Silbergeld 1973 | Allocation: randomised. Participants: people with depression, schizophrenia, anxiety‐type reactions. Intervention: dexamethasone vs placebo. Reason for exclusion: no includable data. |
| Simpson 2005 | Allocation: not randomised (no comparison group, all participants received intervention treatment). |
| Stein 1984 | Allocation: randomised. Participants: people with schizophrenia. Intervention: vasopressin derivative vs placebo, not antiglucocorticoid or related intervention. |
| Tollefson 1998 | Allocation: randomised. Participants: people with schizophrenia. Intervention: olanzapine vs haloperidol, not antiglucocorticoid or related intervention. |
| Young 2004 | Allocation: randomised. Participants: people with bipolar disorder, not psychotic disorder. |
CYP ‐ Cytochrome P mg ‐ Milligrams